kanamycin


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to kanamycin: chloramphenicol, Kanamycin sulfate

kanamycin

 [kan″ah-mi´sin]
a broad-spectrum aminoglycosideantibiotic derived from Streptomyces kanamyceticus; effective against many gram-negative bacteria, and some gram-positive bacteria, including mycobacteria; used as the sulfate salt, administered orally, parenterally, or by inhalation.

kanamycin

(kăn′ə-mī′sĭn)
n.
A broad-spectrum antibiotic, C18H36O11N4, obtained from the soil bacterium Streptomyces kanamyceticus and used to treat a variety of bacterial infections, usually in its sulfate form.

kanamycin

Microbiology A broad-spectrum aminoglycoside antibiotic isolated from Streptomyces kanamyceticus, which is effective against gram-negative rods, and some gram-positive organisms Toxicity Ototoxicity, nephrotoxicity Molecular biology Kanamycin inhibits protein synthesis by binding to the 30s ribosomal subunit and preventing translocation

kanamycin

A broad spectrum aminoglycoside antibiotic derived from a oil actinomycete. Kanamycin is active against GRAM NEGATIVE organisms but is now largely replaced by gentamicin. The aminoglycosides can cause deafness, TINNITUS and kidney damage. The drug is on the WHO official list. A brand name is Kannasyn.
References in periodicals archive ?
Assessment of kanamycin (Kn) as selective agent: The explants with a pre-cultivation time of seven days were cultured in RM supplemented with 0, 25, 50, 100, 200 and 300 mg/L of kanamycin.
Among kanamycin resistant isolates, 77.19% of them were aac(6')-II gene positive, but 17.14% of susceptible isolates possess this gene.
After co-cultivation, cotyledonary node explants were transferred to selective medium (MS + 2 mg L-1 6-BA + 2 mg L-1 AgNO3 + 300 mg L-1 cefotaxime + 50 mg L-1 kanamycin).
8.33% of the isolates showed resistance to a single antimicrobial (kanamycin, tetracycline, ampicillin, and gentamycin).
was found to be maximum sensitive (Table 4) for Ciprofloxacin (83.33%) followed by Norfloxacin (83.33%), Cefotaxime (66.66%) and Ceftriaxone (50%) but less sensitive to Amikacin, Enrofloxacin, Tobramycin, Ampicillin while resistant to Kanamycin, Amoxycillin, Cefoperazone, Cephalexin, Streptomycin and Clindamycin.
Against the aminoglycosides, resistance was 18% to kanamycin and 14% to gentamicin.
Du et al., "Label-free immunosensor for the detection of kanamycin using Ag@[Fe.sub.3][O.sub.4] nanoparticles and thionine mixed graphene sheet," Biosensors and Bioelectronics, vol.
coli M 15 cells harbouring the plasmid pQ30.7 were grown in LB medium containing (75 [micro]g/mL) and kanamycin (25 [micro]g/mL) and induced with 1.0mM IPTG for 4-6 hours.
coli Isolates) Four Five Six Seven Eight NPS 3 1 1 0 0 (1.6%) (0.4%) (0.4%) (0.0%) (0.0%) CSO 10 7 8 9 10 (7.8%) (5.5%) (6.3%) (7.0%) (7.8%) Sample Average Source MAR Index NPS 0.07 CSO 0.36 NPS CSO NPS = nonpoint source; CSO = combined sewer overflow; MAR = multiple antibiotic resistance; Amp = ampicillin; Cam = chloramphenicol; Ctet = chlortetracyline; Kan = kanamycin; Nal = nalidixic acid; Otet = oxytetracycline; Strp = streptomycin; Tet = tetracycline.
Extensively drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis with resistance to at least isoniazid and rifampicin (MDR-TB) and further resistance to a fluoroquinolone and a second-line injectable agent (kanamycin, amikacin, or capreomycin).
For instance, low concentrations of the synthesized nanoparticles can have stronger antibacterial effect in comparison with the common drugs such as kanamycin.
A dramatic diagnostic innovation is a device called the KUDUwave 5000 Portable Diagnostic Audiometer, which detects impending partial or total hearing loss suffered by (among other patient groups) between 30% and 47% of people undergoing treatment for multidrug-resistant tuberculosis (MDR-TB) (about 10 000 at present).!11 The existing MDR-TB hearing loss percentages translate to about 4 000 people on the verge of mild to profound hearing loss as a result of side-effects of the toxic but lifesaving kanamycin, a drug used in the MDRTB treatment cocktail.